Patents by Inventor Upul Bandarage

Upul Bandarage has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 3, 10, AND 12a SUBSTITUTED TETRACYCLINE COMPOUNDS
    Publication number: 20160031802
    Abstract: The present invention pertains to novel 3, 10, and/or 12a-substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.
    Type: Application
    Filed: July 8, 2013
    Publication date: February 4, 2016
    Inventors: Upul Bandarage, Jackson Chen, Mohamed Y. Ismail, Mark L. Nelson, Kwasi Ohemeng
  • 7-substituted tetracycline compounds
    Patent number: 8492365
    Abstract: The present invention pertains, at least in part, to novel 7-substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.
    Type: Grant
    Filed: June 9, 2009
    Date of Patent: July 23, 2013
    Assignees: Trustees of Tufts College, Paratek Pharmaceuticals, Inc.
    Inventors: Mark L. Nelson, Roger Frechette, Peter Viski, Mohamed Ismail, Todd Bowser, Beena Bhatia, David Messersmith, Laura McIntyre, Darrell Koza, Glen Rennie, Paul Sheahan, Paul Hawkins, Atul Verma, Tadeusz Warchol, Upul Bandarage
  • 3, 10, and 12a substituted tetracycline compounds
    Patent number: 8481513
    Abstract: The present invention pertains to novel 3, 10, and/or 12a-substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.
    Type: Grant
    Filed: March 18, 2010
    Date of Patent: July 9, 2013
    Assignee: Paratek Pharmaceuticals, Inc.
    Inventors: Upul Bandarage, Jackson Chen, Mohamed Y. Ismail, Mark L. Nelson, Kwasi Ohemeng
  • Ion channel modulators and methods of uses
    Patent number: 8236815
    Abstract: The invention relates to ion channel modulators of formula Ia, pharmaceutical compositions thereof, and to methods of treating diseases using such compounds where activation or hyperactivity of calcium and/or sodium ion channels is implicated in the disease state.
    Type: Grant
    Filed: March 15, 2010
    Date of Patent: August 7, 2012
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Esther Martinborough, Nicole Zimmermann, Robert B. Perni, Michael Arnost, Upul Bandarage, Francois Maltais, Guy Bemis
  • C-MET PROTEIN KINASE INHIBITORS
    Publication number: 20120065213
    Abstract: Described herein are compounds that are useful as ROCK inhibitors. These compounds, and pharmaceutically acceptable compositions thereof, are useful for treating or lessening the severity of a variety of disorders, including cardiovascular, inflammatory, neurological, or proliferative diseases or disorders.
    Type: Application
    Filed: October 5, 2011
    Publication date: March 15, 2012
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Jeremy Green, Jingrong Cao, Upul Bandarage, Jon Come, Craig Marhefka
  • Selective inhibitors of rock protein kinase and uses thereof
    Patent number: 8058271
    Abstract: Described herein are compounds that are useful as ROCK inhibitors. These compounds, and pharmaceutically acceptable compositions thereof, are useful for treating or lessening the severity of a variety of disorders, including cardiovascular, inflammatory, neurological, or proliferative diseases or disorders.
    Type: Grant
    Filed: May 10, 2007
    Date of Patent: November 15, 2011
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Jeremy Green, Jingrong Cao, Upul Bandarage, Jon Come, Craig Marhefka
  • Substituted Tetracycline Compounds
    Publication number: 20110086822
    Abstract: The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.
    Type: Application
    Filed: October 8, 2010
    Publication date: April 14, 2011
    Inventors: Mark L. Nelson, Kwasi Ohemeng, Roger Frechette, Paul Abato, Victor Amoo, Upul Bandarage, Joel Berniac, Beena Bhatia, Jackson Chen, Mohamed Y. Ismail, Oak Kim, Laura Honeyman, Rachid Mechiche, Andre Pearson, Laxma Reddy Nagavelli, Paul Sheahan, Atul K. Verma, Peter Viski, Tadeusz Warchol
  • Inhibitors of tace
    Patent number: 7919520
    Abstract: The present invention relates to compounds that inhibit TACE, compositions thereof, and methods of using those compounds and compositions for treating diseases.
    Type: Grant
    Filed: November 12, 2008
    Date of Patent: April 5, 2011
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Upul Bandarage, Jon Come, Emanuele Perola, Govinda Rao Bhisetti, Jeffrey O. Saunders, Shi Kai Tian, Tiansheng Wang
  • 3, 10, and 12a substituted tetracycline compounds
    Patent number: 7825105
    Abstract: The present invention pertains to novel 3, 10, and/or 12a-substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.
    Type: Grant
    Filed: February 28, 2005
    Date of Patent: November 2, 2010
    Assignee: Paratek Pharmaceuticals, Inc.
    Inventors: Upul Bandarage, Mohamed Y. Ismail, Mark L. Nelson
  • 3, 10, AND 12a SUBSTITUTED TETRACYCLINE COMPOUNDS
    Publication number: 20100190756
    Abstract: The present invention pertains to novel 3, 10, and/or 12a-substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.
    Type: Application
    Filed: March 18, 2010
    Publication date: July 29, 2010
    Applicant: Paratek Pharmaceuticals, Inc.
    Inventors: Upul Bandarage, Jackson Chen, Mohamed Y. Ismail, Mark L. Nelson, Kwasi Ohemeng
  • Ion Channel Modulators and Methods of Uses
    Publication number: 20100184753
    Abstract: In general, the invention relates to compounds useful as ion channel modulators. It has now been found that compounds of this invention, and pharmaceutically acceptable compositions thereof, are useful as inhibitors of voltage-gated sodium channels and/or calcium channels.
    Type: Application
    Filed: March 15, 2010
    Publication date: July 22, 2010
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Esther Martinborough, Nicole Zimmermann, Robert B. Perni, Michael Arnost, Upul Bandarage, Francois Maltais, Guy Bemis
  • 7-SUBSTITUTED TETRACYCLINE COMPOUNDS
    Publication number: 20090306022
    Abstract: The present invention pertains, at least in part, to novel 7-substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.
    Type: Application
    Filed: June 9, 2009
    Publication date: December 10, 2009
    Applicants: Trustees of Tufts College, Paratek Pharmaceuticals, Inc.
    Inventors: Mark L. Nelson, Roger Frechette, Peter Viski, Mohamed Ismail, Todd Bowser, Beena Bhatia, David Messersmith, Laura McIntyre, Darrell Koza, Glen Rennie, Paul Sheahan, Paul Hawkins, Atul Verma, Tadeusz Warchol, Upul Bandarage
  • 7-substituted tetracycline compounds
    Patent number: 7595309
    Abstract: The present invention pertains, at least in part, to novel 7-substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.
    Type: Grant
    Filed: May 24, 2004
    Date of Patent: September 29, 2009
    Assignees: Trustees of Tufts College, Paratek Pharmaceuticals, Inc.
    Inventors: Mark L. Nelson, Roger Frechette, Peter Viski, Beena Bhatia, David Messersmith, Mohamed Y. Ismail, Todd Bowser, Laura McIntyre, Darrell J. Koza, Glen Rennie, Paul Sheahan, Paul Hawkins, Atul K. Verma, Tadeusz Warchol, Upul Bandarage
  • INHIBITORS OF TACE
    Publication number: 20090176782
    Abstract: The present invention relates to compounds that inhibit TACE, compositions thereof, and methods of using those compounds and compositions for treating diseases.
    Type: Application
    Filed: November 12, 2008
    Publication date: July 9, 2009
    Inventors: Upul Bandarage, Jon Come, Emanuele Perola, Govinda Rao Bhisetti, Jeffrey O. Saunders, Shi Kai Tian, Tiansheng Wang
  • Azaindoles useful as inhibitors of rock and other protein kinases
    Patent number: 7514448
    Abstract: The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
    Type: Grant
    Filed: April 4, 2005
    Date of Patent: April 7, 2009
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Jeremy Green, Andrew Miller, Juan-Miguel Jimenez, Craig Marhefka, Jingrong Cao, John Court, Upul Bandarage, Huai Gao, Suganthini Nanthakumar
  • Inhibitors of TACE
    Patent number: 7485664
    Abstract: The present invention relates to compounds that inhibit TACE, compositions thereof, and methods of using those compounds and compositions for treating diseases.
    Type: Grant
    Filed: December 19, 2003
    Date of Patent: February 3, 2009
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Upul Bandarage, Jon H. Come, Emanuele Perola, Govinda Rao Bhisetti, Jeffrey O. Saunders, Tiansheng Wang, Shi-Kai Tian
  • Modulators of muscarinic receptors
    Publication number: 20080033002
    Abstract: The present invention relates to modulators of muscarinic receptors. The present invention also provides compositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases.
    Type: Application
    Filed: June 28, 2007
    Publication date: February 7, 2008
    Inventors: Upul Bandarage, Jinwang Xu, Robert Davies, Paul Charifson, Rieko Arimoto
  • Selective inhibitors of rock protein kinase and uses thereof
    Publication number: 20070270386
    Abstract: Described herein are compounds that are useful as ROCK inhibitors. These compounds, and pharmaceutically acceptable compositions thereof, are useful for treating or lessening the severity of a variety of disorders, including cardiovascular, inflammatory, neurological, or proliferative diseases or disorders.
    Type: Application
    Filed: May 10, 2007
    Publication date: November 22, 2007
    Inventors: Jeremy Green, Jingrong Cao, Upul Bandarage, Jon Come, Craig Marhefka
  • Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
    Publication number: 20070060571
    Abstract: The present invention describes novel nitrosated and/or nitrosylated cyclooxygenase 2 (COX-2) inhibitors and novel compositions comprising at least one nitrosated and/or nitrosylated cyclooxygenase 2 (COX-2) inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or optionally, at least one therapeutic agent. The present invention also provides novel compositions comprising at least one parent COX-2 inhibitor and at least one nitric oxide donor, and, optionally, at least one therapeutic agent.
    Type: Application
    Filed: November 15, 2006
    Publication date: March 15, 2007
    Applicant: NitroMed, Inc.
    Inventors: Ramani Bandarage, Upul Bandarage, Xinqin Fang, David Garvey, L. Letts, Joseph Schroeder, Sang Tam
  • Modulators of muscarinic receptors
    Publication number: 20060270653
    Abstract: The present invention relates to modulators of muscarinic receptors. The present invention also provides compositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases.
    Type: Application
    Filed: November 29, 2005
    Publication date: November 30, 2006
    Inventors: Ioana Drutu, Dennis Hurley, Upul Bandarage, Daniele Bergeron, Paul Charifson, Robert Davies, Miguel Blanco, Lewis Makings, Akiko Nakatani, Gabriel Raffai